Evidence map›Paper›PMID 37700268›Full record

ArticleBMC public health2023

Triple therapy for Helicobacter pylori eradication and the risk of hypoglycemia in patients with diabetes: a population-based cohort study.

Anne Chang, Anna Chang, Wan-Ting Chen, Lung Chan, Chien-Tai Hong, Li-Nien Chien

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Novel therapeutic regimens againstFrontiers in microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Anne ChangDepartment of Endocrinology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Anna ChangDepartment of Neurology, Shin Kong Wu Huo-Shih Memorial Hospital, Taipei, Taiwan.
Wan-Ting ChenHealth Data Analytics and Statistics Center, Taipei Medical University, Taipei, Taiwan.
Lung ChanDepartment of Neurology, Taipei Medical University-Shuang Ho Hospital, No. 291, Zhongzheng Rd, Zhonghe District, New Taipei City, 23561, Taiwan.
Chien-Tai Hong *Department of Neurology, Taipei Medical University-Shuang Ho Hospital, No. 291, Zhongzheng Rd, Zhonghe District, New Taipei City, 23561, Taiwan. ct.hong@tmu.edu.tw.
Li-Nien Chien *Institution of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. linien.chien@nycu.edu.tw.
Taipei Medical University-Shuang Ho Hospital · TWNational Yang Ming Chiao Tung University · TWShin Kong WHS Memorial Hospital · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of type 2 diabetes mellitus has risen globally, from 108 million cases in 1980 to 422 million cases in 2014. Although controlling glycemic levels in patients with diabetes is crucial, insulin and sulfonylureas can cause hypoglycemic episodes and even potentially fatal events such as comas, seizures, life-threatening arrhythmias, and myocardial infarctions. Several antibiotics have been documented to cause hypoglycemic episodes; the use of antibiotics along with insulin or sulfonylureas might further increase the risk of hypoglycemia. Therefore, researchers must determine which antibiotics carry a risk of inducing severe hypoglycemic events. The prevalence of H. pylori infection remains high in most countries, and the infection is often treated with triple therapy involving amoxicillin, clarithromycin, and a proton pump inhibitor (PPI). Several case reports have reported that hypoglycemia can occur when used with patients who also take diabetes medication. Therefore, we hypothesized that patients with diabetes have an increased risk of hypoglycemic episodes when being treated with triple therapy for H. pylori infection. By analyzing medical records from Taiwan's National Health Insurance Research Database, we found a significant association between hypoglycemia and triple therapy treatment for diabetic patients with peptic ulcer disease. Prescribing triple therapy to patients with diabetes and peptic ulcers significantly increased the risk of a hypoglycemic episode (adjusted odds ratio [aOR] = 1.75, 95% confidence interval [CI]: 1.64 to 1.88, P < 0.001). Similarly, the highest aOR (5.77, 95% CI 4.82 to 6.92) was found in patients with diabetes and peptic ulcers who had hypoglycemic episodes within 30 days after triple therapy treatment. Many patients with diabetes require H.pylori eradication for peptic ulcer treatment, and vigilance toward the risk of hypoglycemia in this population is thus necessary.

Indexed as

Diabetes Mellitus, Type 2Helicobacter pyloriHypoglycemiaAnti-Bacterial AgentsCohort StudiesHumansHypoglycemic AgentsInsulinAnti-Bacterial AgentsHypoglycemic AgentsInsulinH.pylori eradicationHypoglycemiaType 2 diabetes mellitus

Identifiers

PMID37700268
PMCPMC10496377
OpenAlexW4386688611

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.